Related Experiment Video
Updated: Aug 14, 2026
An Orthotopic Resectional Mouse Model of Pancreatic Cancer
Published on: September 24, 2020
Treatment of metastatic pancreatic adenocarcinoma: a comprehensive review
1Division of Medical Oncology, St. Luke's-Roosevelt Hospital Center, Columbia University, New York, New York 10019, USA.
Abstract:
The current standard therapy for metastatic pancreatic adenocarcinoma is the single-agent gemcitabine, by the increasingly used fixed rate infusion of 10 mg/m2/min. There is strong reason to anticipate that additional benefits will accrue with gemcitabine-based combination chemotherapy. Gemcitabine and CPT-11 are synergistic with many drugs and non-cross-resistant with each other. Rigorous clinical investigations will be performed in an effort to identify optimal drug sequence and schedules for these novel combinations.
